Neurizon inks $1.5M loan against R&D Tax Rebate
Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
OCA | Ann: Investor Day - 16 September 2025 | 23/07/25 | 0 | 88 | |||
|
|||||||
OCA | Ann: Annual Meeting 2025 Results | 27/06/25 | 0 | 109 | |||
|
|||||||
OCA | Ann: Annual Meeting 2025 Presentations | 27/06/25 | 0 | 115 | |||
|
|||||||
OCA | Ann: Meadowbank Presentation | 23/06/25 | 0 | 104 | |||
|
|||||||
OCA | Ann: Capital Change Notice | 23/06/25 | 0 | 136 | |||
|
|||||||
OCA | Ann: FY2025 Climate-related Disclosures Report | 06/06/25 | 0 | 157 | |||
|
|||||||
OCA | Ann: Notice of Meeting | 27/05/25 | 0 | 162 | |||
|
|||||||
OCA | Ann: Investor Presentation | 22/05/25 | 0 | 141 | |||
|
See All Discussions